WallStreetZenWallStreetZen

NASDAQ: IKNA
Ikena Oncology Inc Stock Forecast, Predictions & Price Target

Analyst price target for IKNA

Based on 2 analysts offering 12 month price targets for Ikena Oncology Inc.
Min Forecast
$8.00+510.69%
Avg Forecast
$9.50+625.19%
Max Forecast
$11.00+739.69%

Should I buy or sell IKNA stock?

Based on 2 analysts offering ratings for Ikena Oncology Inc.
Buy
Strong Buy
0 analysts 0%
Buy
2 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their IKNA stock forecasts and price targets.

IKNA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-03-19
lockedlocked$00.00+00.00%2024-01-19

1 of 1

Forecast return on equity

Is IKNA forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.16%

Forecast return on assets

Is IKNA forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

IKNA revenue forecast

What is IKNA's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$10.2M+11.35%
Avg 2 year Forecast
$20.0M+118.34%
Avg 3 year Forecast
$30.0M+227.51%
IKNA's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

IKNA revenue growth forecast

How is IKNA forecast to perform vs Biotechnology companies and vs the US market?
Company
48.45%
Industry
37.04%
Market
9.92%
IKNA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
IKNA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

IKNA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
IKNA$1.31$9.50+625.19%Buy
EQ$1.81$5.00+176.24%Buy
RLYB$1.65$8.90+439.39%Buy
ALGS$0.82N/AN/A
MNOV$1.32N/AN/A

Ikena Oncology Stock Forecast FAQ

Is Ikena Oncology Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: IKNA) stock is to Buy IKNA stock.

Out of 2 analysts, 0 (0%) are recommending IKNA as a Strong Buy, 2 (100%) are recommending IKNA as a Buy, 0 (0%) are recommending IKNA as a Hold, 0 (0%) are recommending IKNA as a Sell, and 0 (0%) are recommending IKNA as a Strong Sell.

If you're new to stock investing, here's how to buy Ikena Oncology stock.

What is IKNA's revenue growth forecast for 2024-2026?

(NASDAQ: IKNA) Ikena Oncology's forecast annual revenue growth rate of 48.45% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.04%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.92%.

Ikena Oncology's revenue in 2024 is $9,160,000.On average, 3 Wall Street analysts forecast IKNA's revenue for 2024 to be $492,232,732, with the lowest IKNA revenue forecast at $48,258,111, and the highest IKNA revenue forecast at $752,826,532. On average, 2 Wall Street analysts forecast IKNA's revenue for 2025 to be $965,162,220, with the lowest IKNA revenue forecast at $965,162,220, and the highest IKNA revenue forecast at $965,162,220.

In 2026, IKNA is forecast to generate $1,447,743,330 in revenue, with the lowest revenue forecast at $965,162,220 and the highest revenue forecast at $1,930,324,440.

What is IKNA's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: IKNA) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is IKNA's Price Target?

According to 2 Wall Street analysts that have issued a 1 year IKNA price target, the average IKNA price target is $9.50, with the highest IKNA stock price forecast at $11.00 and the lowest IKNA stock price forecast at $8.00.

On average, Wall Street analysts predict that Ikena Oncology's share price could reach $9.50 by Mar 19, 2025. The average Ikena Oncology stock price prediction forecasts a potential upside of 625.19% from the current IKNA share price of $1.31.

What is IKNA's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: IKNA) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.